Karyopharm Reports Positive Top-Line Phase 2b STORM Results and Reviews the Planned Development Path for Selinexor in Multiple Myeloma
Go back to Karyopharm Reports Positive Top-Line Phase 2b STORM Results and Reviews the Planned Development Path for Selinexor in Multiple Myeloma| KARYOPHARM THERAP (NASDAQ: KPTI) | Delayed: 1.93 +0.12 (6.63%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.81 | 52 Week High | $19.41 | |||
| Open | $1.88 | 52 Week Low | $4.83 | |||
| Day High | $1.96 | P/E | N/A | |||
| Day Low | $1.82 | EPS | $-2.74 | |||
| Volume | 1,145,196 | |||||
